Citadel Advisors’s Purple Biotech PPBT Stock Holding History

Citadel Advisors’s Portfolio PPBT Stock Details PPBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,750	Closed	-$31.2K	–	13953
2025 Q4	$31.2K	Buy	+4,750	New	+$34.5K	﹤0.01%	12216
2023 Q4	–	Sell	-8	Closed	-$1.73K	–	15017
2023 Q3	$1.73K	Sell	8 -10	-56%	-$2.38K	﹤0.01%	13818
2023 Q2	$4.9K	Sell	18 -3	-14%	-$1.08K	﹤0.01%	13552
2023 Q1	$7.39K	Buy	21 +12	+133%	+$4.5K	﹤0.01%	13731
2022 Q4	$2.35K	Buy	+9	New	+$3.45K	﹤0.01%	14348
2022 Q2	–	Sell	-85	Closed	-$67K	–	13824
2022 Q1	$67K	Sell	85 -88	-51%	-$56.8K	﹤0.01%	12607
2021 Q4	$134K	Sell	173 -1	-0.6%	-$852	﹤0.01%	12409
2021 Q3	$159K	Sell	174 -108	-38%	-$105K	﹤0.01%	12297
2021 Q2	$275K	Buy	+282	New	+$259K	﹤0.01%	11475

Other funds holding PPBT

SmartHarvest Portfolios Poulsbo, Washington $309M AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

IFG Advisory Atlanta, Georgia $2.85B AUM 26.07% 1-Year Est. Return

Citadel Advisors's PPBT Position: Q2 2026 in Review

Citadel Advisors opened a new position in Purple Biotech (PPBT) in Q2 2026: 13,166 shares worth $22.1K. The stake represents ﹤0.01% of the portfolio and ranks #13382 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in PPBT as recently as Q4 2025.

Citadel Advisors first reported a position in PPBT in Q2 2016 and has held it in 18 quarters since. The position peaked at $400K in Q2 2020. 13 funds tracked by Wall St. Rank hold PPBT as of Q2 2026.

Citadel Advisors held 13,166 shares of Purple Biotech worth $22.1K as of Q2 2026.
Purple Biotech was a new Citadel Advisors position in Q2 2026.
Purple Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #13382 holding.
Citadel Advisors first reported a position in Purple Biotech in Q2 2016 and has held it in 18 quarters since.
Citadel Advisors's Purple Biotech position peaked at $400K in Q2 2020.
13 funds tracked by Wall St. Rank held Purple Biotech as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.